Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Nature

Volumn 534, Issue 7607, 2016, Pages 396-401

  Kranz, Lena M ^a,b   Diken, Mustafa ^a,c   Haas, Heinrich ^c   Kreiter, Sebastian ^a,c   Loquai, Carmen ^a   Reuter, Kerstin C ^c   Meng, Martin ^c   Fritz, Daniel ^c   Vascotto, Fulvia ^a   Hefesha, Hossam ^c   Grunwitz, Christian ^b,c   Vormehr, Mathias ^b,c   Hüsemann, Yves ^c   Selmi, Abderraouf ^a,b   Kuhn, Andreas N ^c   Buck, Janina ^c   Derhovanessian, Evelyna ^c   Rae, Richard ^a   Attig, Sebastian ^a,b   Diekmann, Jan ^c   Jabulowsky, Robert A ^c   Heesch, Sandra ^c   Hassel, Jessica ^d   Langguth, Peter ^b   Grabbe, Stephan ^a   Huber, Christoph ^a,c   Türeci, Özlem ^e   Sahin, Ugur ^a,b,c   more..

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c BIONTECH AG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Cluster for Individualized Immune Intervention   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIPOPLEX; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; RIBONUCLEASE; RNA; TOLL LIKE RECEPTOR 7; TPTE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIGEN; DRUG CARRIER; INTERFERON; MEMBRANE PROTEIN; NANOPARTICLE; TLR7 PROTEIN, MOUSE; VIRUS ANTIGEN;

ANTIGEN; BIOENGINEERING; CANCER; CELLS AND CELL COMPONENTS; IMMUNOASSAY; LIGAND; MATURATION; PHOSPHOLIPID; PROTEIN; RNA; TUMOR; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISPERSION; DRUG DOSE INCREASE; FLU LIKE SYNDROME; HUMAN; INFLAMMATION; LIPOSOMAL GENE DELIVERY SYSTEM; MACROPHAGE; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION; ZETA POTENTIAL; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MALE; METABOLISM; PROCEDURES; SECRETION (PROCESS); STATIC ELECTRICITY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; AUTOANTIGENS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MACROPHAGES; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NANOPARTICLES; RNA; STATIC ELECTRICITY; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7;

EID: 84975832642     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18300     Document Type: Article

References (52)

1. Zinkernagel, R. M. et al. Antigen localisation regulates immune responses in a dose-And time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 156, 199-209 (1997).
2. Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity 25, 373-381 (2006).
3. Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
4. Sahin, U., Karikó, K. & Töreci, Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759-780 (2014).
5. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
6. Tacken, P. J., de Vries, I. J. M., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
7. Phua, K. K. L. Towards targeted delivery systems: ligand conjugation strategies for mRNA nanoparticle tumor vaccines. J. Immunol. Res. 680620 (2015).
8. Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655-672 (2014).
9. Brito, L. A. et al. A cationic nanoemulsion for the delivery of next generation RNA vaccines. Mol. Ther. 22, 2118-2129 (2014).
10. Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251-259 (2013).
11. Zhou, W. Z. et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum. Gene Ther. 10, 2719-2724 (1999).
12. Hess, P. R., Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Vaccination with mRNAs encoding tumor-Associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 55, 672-683 (2006).
13. Perche, F. et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445-453 (2011).
14. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941-951 (2015).
15. Lee, E. R. et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7, 1701-1717 (1996).
16. Liu, Y. et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15, 167-173 (1997).
17. Diken, M. et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 18, 702-708 (2011).
18. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400 (1995).
19. Platt, C. D. et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl Acad. Sci. USA 107, 4287-4292 (2010).
20. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa & C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
21. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
22. Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009-1015 (2003).
23. Bacher, N. et al. Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res. 73, 5647-5656 (2013).
24. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405-414 (2015).
25. Janeway, C. A. Jr The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
26. Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
27. Swiecki, M., Gilfillan, S., Vermi, W., Wang, Y. & Colonna, M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8+ T cell accrual. Immunity 33, 955-966 (2010).
28. Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253-3261 (2006).
29. Möller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994).
30. Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-Associated antigens. Immunity 17, 211-220 (2002).
31. Huang, A. Y. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl Acad. Sci. USA 93, 9730-9735 (1996).
32. Lin, K.-Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 21-26 (1996).
33. Chuang, C.-M., Monie, A., Wu, A. & Hung, C.-F. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J. Biomed. Sci. 16, 49 (2009).
34. Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009-4017 (2006).
35. Kreiter, S. et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. 180, 309-318 (2008).
36. Kuhn, A. N. et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 17, 961-971 (2010).
37. Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529-538 (2000).
38. Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
39. Kreiter, S. et al. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol. Immunother. 56, 1577-1587 (2007).
40. Bangham, A. D., Hill, M. W. & Miller, N. G. A. in Methods in Membrane Biology (ed. Korn, E. D.) 1-68 (Springer US, 1974).
41. Duzgunes, N. in Methods in Enzymology (Academic Press Inc, 2009).
42. Batzri, S. & Korn, E. D. Single bilayer liposomes prepared without sonication. Biochim. Biophys. Acta 298, 1015-1019 (1973).
43. Barichello, J. M., Ishida, T. & Kiwada, H. Complexation of siRNA and pDNA with cationic liposomes: The important aspects in lipoplex preparation. Methods Mol. Biol. 605, 461-472 (2010).
44. Racoosin, E. L. & Swanson, J. A. Macrophage colony-stimulating factor (rM-CSF) stimulates pinocytosis in bone marrow-derived macrophages. J. Exp. Med. 170, 1635-1648 (1989).
45. Sarkar, K., Kruhlak, M. J., Erlandsen, S. L. & Shaw, S. Selective inhibition by rottlerin of macropinocytosis in monocyte-derived dendritic cells. Immunology 116, 513-524 (2005).
46. Bar-On, L. & Jung, S. Defining in vivo dendritic cell functions using CD11c-DTR transgenic mice. Methods Mol. Biol. 595, 429-442 (2010).
47. Aichele, P. et al. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J. Immunol. 171, 1148-1155 (2003).
48. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36, 641-645 (1966).
49. Chen, Y. T. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914-1918 (1997).
50. Brichard, V. et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489-495 (1993).
51. Gaugler, B. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930 (1994).
52. Simon, P. et al. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol. Res. 2, 1230-1244 (2014).